ENSA expression correlates with attenuated tumor propagation in liver cancer

Yao Li Chen, Ming Han Kuo, Ping Yi Lin, Wan Ling Chuang, Chia Chen Hsu, Pei Yi Chu, Chia Huei Lee, Hui-ming Huang, Yu Wei Leu, Shu Huei Hsiao

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Endosulfine alpha (ENSA) is an endogenous ligand of sulfonylurea receptor that was reported to be associated with an ATP-dependent potassium channel that controls insulin release and the onset of type 2 diabetes. ENSA also interacts with microtubule-associated serine/threonine-protein kinase-like (MASTL) to regulate the cell cycle. Previously, we identified ENSA as a possible bivalent gene in mesenchymal stem cells (MSCs) and hypothesized its methylation might determine cellular differentiation and transformation. Because there was no link between aberrant ENSA expression and tumorigenesis, we aimed to determine if ENSA is abnormally regulated in liver cancer and plays a role in liver cancer propagation. The epigenetic states of the ENSA promoter were evaluated in different cancer cell lines and patient samples. ENSA was overexpressed in a liver cancer cell line, and its interaction with MASTL and possible tumor suppression capabilities were also determined in cultured cells and mice. Distinct ENSA promoter methylation was observed in liver cancer (n = 100 pairs) and breast cancer (n = 100 pairs). ENSA was predominantly hypomethylated in liver cancer but was hypermethylated in breast cancer. Overexpressed ENSA interacts with MASTL and suppresses hepatic tumor growth. We also found that ENSA is hypermethylated in CD90-expressing (CD90+) cells compared to CD90 non-expressing (CD90-) liver cancer cells. These data reveal ENSA methylation changes during hepatic tumor evolution. Overexpressed ENSA suppresses tumor growth in an established hepatic cell line whereas hypermethylated ENSA might help maintain liver cancer initiating cells.

Original languageEnglish (US)
Pages (from-to)56-61
Number of pages6
JournalBiochemical and Biophysical Research Communications
Volume442
Issue number1-2
DOIs
StatePublished - Dec 6 2013
Externally publishedYes

Fingerprint

Liver Neoplasms
Liver
Tumors
Neoplasms
Cells
Methylation
Protein-Serine-Threonine Kinases
Microtubules
endosulfine
Cell Line
Sulfonylurea Receptors
Breast Neoplasms
Potassium Channels
Medical problems
Growth
Stem cells
Mesenchymal Stromal Cells
Epigenomics
Type 2 Diabetes Mellitus
Hepatocytes

Keywords

  • Chromatin immunoprecipitation
  • DNA methylation
  • Epigenetic
  • Liver cancer

ASJC Scopus subject areas

  • Biochemistry
  • Biophysics
  • Cell Biology
  • Molecular Biology

Cite this

Chen, Y. L., Kuo, M. H., Lin, P. Y., Chuang, W. L., Hsu, C. C., Chu, P. Y., ... Hsiao, S. H. (2013). ENSA expression correlates with attenuated tumor propagation in liver cancer. Biochemical and Biophysical Research Communications, 442(1-2), 56-61. https://doi.org/10.1016/j.bbrc.2013.10.165

ENSA expression correlates with attenuated tumor propagation in liver cancer. / Chen, Yao Li; Kuo, Ming Han; Lin, Ping Yi; Chuang, Wan Ling; Hsu, Chia Chen; Chu, Pei Yi; Lee, Chia Huei; Huang, Hui-ming; Leu, Yu Wei; Hsiao, Shu Huei.

In: Biochemical and Biophysical Research Communications, Vol. 442, No. 1-2, 06.12.2013, p. 56-61.

Research output: Contribution to journalArticle

Chen, YL, Kuo, MH, Lin, PY, Chuang, WL, Hsu, CC, Chu, PY, Lee, CH, Huang, H, Leu, YW & Hsiao, SH 2013, 'ENSA expression correlates with attenuated tumor propagation in liver cancer', Biochemical and Biophysical Research Communications, vol. 442, no. 1-2, pp. 56-61. https://doi.org/10.1016/j.bbrc.2013.10.165
Chen, Yao Li ; Kuo, Ming Han ; Lin, Ping Yi ; Chuang, Wan Ling ; Hsu, Chia Chen ; Chu, Pei Yi ; Lee, Chia Huei ; Huang, Hui-ming ; Leu, Yu Wei ; Hsiao, Shu Huei. / ENSA expression correlates with attenuated tumor propagation in liver cancer. In: Biochemical and Biophysical Research Communications. 2013 ; Vol. 442, No. 1-2. pp. 56-61.
@article{8e188a9c5f904345992ba2c5ae819f2a,
title = "ENSA expression correlates with attenuated tumor propagation in liver cancer",
abstract = "Endosulfine alpha (ENSA) is an endogenous ligand of sulfonylurea receptor that was reported to be associated with an ATP-dependent potassium channel that controls insulin release and the onset of type 2 diabetes. ENSA also interacts with microtubule-associated serine/threonine-protein kinase-like (MASTL) to regulate the cell cycle. Previously, we identified ENSA as a possible bivalent gene in mesenchymal stem cells (MSCs) and hypothesized its methylation might determine cellular differentiation and transformation. Because there was no link between aberrant ENSA expression and tumorigenesis, we aimed to determine if ENSA is abnormally regulated in liver cancer and plays a role in liver cancer propagation. The epigenetic states of the ENSA promoter were evaluated in different cancer cell lines and patient samples. ENSA was overexpressed in a liver cancer cell line, and its interaction with MASTL and possible tumor suppression capabilities were also determined in cultured cells and mice. Distinct ENSA promoter methylation was observed in liver cancer (n = 100 pairs) and breast cancer (n = 100 pairs). ENSA was predominantly hypomethylated in liver cancer but was hypermethylated in breast cancer. Overexpressed ENSA interacts with MASTL and suppresses hepatic tumor growth. We also found that ENSA is hypermethylated in CD90-expressing (CD90+) cells compared to CD90 non-expressing (CD90-) liver cancer cells. These data reveal ENSA methylation changes during hepatic tumor evolution. Overexpressed ENSA suppresses tumor growth in an established hepatic cell line whereas hypermethylated ENSA might help maintain liver cancer initiating cells.",
keywords = "Chromatin immunoprecipitation, DNA methylation, Epigenetic, Liver cancer",
author = "Chen, {Yao Li} and Kuo, {Ming Han} and Lin, {Ping Yi} and Chuang, {Wan Ling} and Hsu, {Chia Chen} and Chu, {Pei Yi} and Lee, {Chia Huei} and Hui-ming Huang and Leu, {Yu Wei} and Hsiao, {Shu Huei}",
year = "2013",
month = "12",
day = "6",
doi = "10.1016/j.bbrc.2013.10.165",
language = "English (US)",
volume = "442",
pages = "56--61",
journal = "Biochemical and Biophysical Research Communications",
issn = "0006-291X",
publisher = "Academic Press Inc.",
number = "1-2",

}

TY - JOUR

T1 - ENSA expression correlates with attenuated tumor propagation in liver cancer

AU - Chen, Yao Li

AU - Kuo, Ming Han

AU - Lin, Ping Yi

AU - Chuang, Wan Ling

AU - Hsu, Chia Chen

AU - Chu, Pei Yi

AU - Lee, Chia Huei

AU - Huang, Hui-ming

AU - Leu, Yu Wei

AU - Hsiao, Shu Huei

PY - 2013/12/6

Y1 - 2013/12/6

N2 - Endosulfine alpha (ENSA) is an endogenous ligand of sulfonylurea receptor that was reported to be associated with an ATP-dependent potassium channel that controls insulin release and the onset of type 2 diabetes. ENSA also interacts with microtubule-associated serine/threonine-protein kinase-like (MASTL) to regulate the cell cycle. Previously, we identified ENSA as a possible bivalent gene in mesenchymal stem cells (MSCs) and hypothesized its methylation might determine cellular differentiation and transformation. Because there was no link between aberrant ENSA expression and tumorigenesis, we aimed to determine if ENSA is abnormally regulated in liver cancer and plays a role in liver cancer propagation. The epigenetic states of the ENSA promoter were evaluated in different cancer cell lines and patient samples. ENSA was overexpressed in a liver cancer cell line, and its interaction with MASTL and possible tumor suppression capabilities were also determined in cultured cells and mice. Distinct ENSA promoter methylation was observed in liver cancer (n = 100 pairs) and breast cancer (n = 100 pairs). ENSA was predominantly hypomethylated in liver cancer but was hypermethylated in breast cancer. Overexpressed ENSA interacts with MASTL and suppresses hepatic tumor growth. We also found that ENSA is hypermethylated in CD90-expressing (CD90+) cells compared to CD90 non-expressing (CD90-) liver cancer cells. These data reveal ENSA methylation changes during hepatic tumor evolution. Overexpressed ENSA suppresses tumor growth in an established hepatic cell line whereas hypermethylated ENSA might help maintain liver cancer initiating cells.

AB - Endosulfine alpha (ENSA) is an endogenous ligand of sulfonylurea receptor that was reported to be associated with an ATP-dependent potassium channel that controls insulin release and the onset of type 2 diabetes. ENSA also interacts with microtubule-associated serine/threonine-protein kinase-like (MASTL) to regulate the cell cycle. Previously, we identified ENSA as a possible bivalent gene in mesenchymal stem cells (MSCs) and hypothesized its methylation might determine cellular differentiation and transformation. Because there was no link between aberrant ENSA expression and tumorigenesis, we aimed to determine if ENSA is abnormally regulated in liver cancer and plays a role in liver cancer propagation. The epigenetic states of the ENSA promoter were evaluated in different cancer cell lines and patient samples. ENSA was overexpressed in a liver cancer cell line, and its interaction with MASTL and possible tumor suppression capabilities were also determined in cultured cells and mice. Distinct ENSA promoter methylation was observed in liver cancer (n = 100 pairs) and breast cancer (n = 100 pairs). ENSA was predominantly hypomethylated in liver cancer but was hypermethylated in breast cancer. Overexpressed ENSA interacts with MASTL and suppresses hepatic tumor growth. We also found that ENSA is hypermethylated in CD90-expressing (CD90+) cells compared to CD90 non-expressing (CD90-) liver cancer cells. These data reveal ENSA methylation changes during hepatic tumor evolution. Overexpressed ENSA suppresses tumor growth in an established hepatic cell line whereas hypermethylated ENSA might help maintain liver cancer initiating cells.

KW - Chromatin immunoprecipitation

KW - DNA methylation

KW - Epigenetic

KW - Liver cancer

UR - http://www.scopus.com/inward/record.url?scp=84889685785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84889685785&partnerID=8YFLogxK

U2 - 10.1016/j.bbrc.2013.10.165

DO - 10.1016/j.bbrc.2013.10.165

M3 - Article

VL - 442

SP - 56

EP - 61

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

SN - 0006-291X

IS - 1-2

ER -